The role of uric acid in the pathogenesis of human cardiovascular disease

Heart

Volumn 99, Issue 11, 2013, Pages 759-766

  Kanbay, Mehmet ^a   Segal, Mark ^b   Afsar, Baris ^c   Kang, Duk Hee ^d   Rodriguez Iturbe, Bernardo ^e   Johnson, Richard J ^f  

^a Medeniyet University   (Turkey)

^b UNIVERSITY OF FLORIDA   (United States)

^c Konya Numune State Hospital   (Turkey)

^d Ewha Womans University   (South Korea)

^e HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CHLORTALIDONE; OXIPURINOL; PLACEBO; PROBENECID; URIC ACID; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; INNATE IMMUNITY; INTRACORONARY INFUSION; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPRODUCIBILITY; REVIEW; URIC ACID BLOOD LEVEL; VASOCONSTRICTION;

CORONARY ARTERY DISEASE; HEART FAILURE;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERURICEMIA; OXIDATIVE STRESS; URIC ACID; VASOCONSTRICTION;

EID: 84877608199     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302535     Document Type: Review

References (140)

1. Wu XW, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992;34:78-84.
2. Oda M, Satta Y, Takenaka O, et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002;19:640-53. (Pubitemid 34521296)
3. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-62. (Pubitemid 12216861)
4. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355-60. (Pubitemid 35006723)
5. Johnson RJ, Andrews P. Fructose, Uricase, and the Back-to-Africa Hypothesis. Evol Anthropol 2010;19:250-7.
6. Johnson RJ, Sautin YY, Oliver WJ, et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol 2009;179:67-76.
7. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005;25:3-8. (Pubitemid 40128142)
8. Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007;86:899-906. (Pubitemid 47538288)
9. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51. (Pubitemid 40686653)
10. Johnson RJ. The fat switch. Chicago: mercola.com; 2012.
11. Selby JV, Friedman GD, Quesenberry CP Jr. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990;131:1017-27. (Pubitemid 20178623)
12. Hunt SC, Stephenson SH, Hopkins PN, et al. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991;17:969-76.
13. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994;8:677-81. (Pubitemid 24276965)
14. Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 1999;13:13-21. (Pubitemid 29042140)
15. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001;19:1209-15. (Pubitemid 32595276)
16. Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001;24:531-6. (Pubitemid 33048919)
17. Nagahama K, Iseki K, Inoue T, et al. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004;27:227-33. (Pubitemid 38594393)
18. Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33. (Pubitemid 40066409)
19. Shankar A, Klein R, Klein BE, et al. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens 2006;20:937-45. (Pubitemid 44782827)
20. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006;48:1031-6. (Pubitemid 44772704)
21. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006;48:1037-42. (Pubitemid 44772705)
22. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303. (Pubitemid 46143005)
23. Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 2009;55:2026-34.
24. Forman JP, Choi H, Curhan GC. Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 2009;169:155-62.
25. Yang T, Chu CH, Bai CH, et al. Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study. Metabolism 2012;61:1747-55.
26. Grayson PC, Kim SY, Lavalley M, et al. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;63:102-10.
27. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6. (Pubitemid 34252813)
28. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 2002;282:F991-7. (Pubitemid 34654464)
29. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-47. (Pubitemid 40019245)
30. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol 2008;295:F1134-41.
31. Sanchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol 2007;292:F1238-44. (Pubitemid 46572443)
32. Johnson RJ, Herrera-Acosta J, Schreiner GF, et al. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-23. (Pubitemid 34984641)
33. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, et al. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol 2004;286:F606-16. (Pubitemid 38365077)
34. Feig DI. Uric acid and hypertension. Semin Nephrol 2011;31:441-6.
35. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003;42:247-52. (Pubitemid 37093468)
36. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011;6:1887-94.
37. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-33. (Pubitemid 350193621)
38. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Jama 2002;288:2981-97.
39. Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006;37:1503-7. (Pubitemid 44305733)
40. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92.
41. Lehto S, Niskanen L, Ronnemaa T, et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998;29:635-9. (Pubitemid 28145791)
42. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83, 683 Austrian men. Clin Chem 2008;54:273-84. (Pubitemid 351302628)
43. Ekundayo OJ, Dell'Italia LJ, Sanders PW, et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol 2010;142:279-87.
44. Reyes AJ, Leary WP. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid? Cardiovasc Drugs Ther 2002;16:485-7. (Pubitemid 36520995)
45. Ernst ME, Neaton JD, Grimm RH Jr, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension 2011;58:1001-7.
46. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8. (Pubitemid 43740274)
47. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-54.
48. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9. (Pubitemid 38251080)
49. Reungjui S, Roncal CA, Mu W, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 2007;18:2724-31. (Pubitemid 47531199)
50. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604-8. (Pubitemid 21906552)
51. Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005;25:425-33. (Pubitemid 41433885)
52. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005;16:3553-62.
53. Kanbay M, Sanchez-Lozada LG, Franco M, et al. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant 2011;26:430-7.
54. Manolio TA, Olson J, Longstreth WT. Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep 2003;5:255-61. (Pubitemid 38914969)
55. Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951-6. (Pubitemid 36944787)
56. Newman EJ, Rahman FS, Lees KR, et al. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metab Res Rev 2006;22:79-82. (Pubitemid 43154466)
57. Kanellis J, Johnson RJ. Editorial comment-Elevated uric acid and ischemic stroke: accumulating evidence that it is injurious and not neuroprotective. Stroke 2003;34:1956-7. (Pubitemid 36944788)
58. Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002;33:1048-52. (Pubitemid 34293590)
59. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-65. (Pubitemid 27208159)
60. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814-22. (Pubitemid 28556651)
61. Ndrepepa G, Braun S, Haase HU, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol 2012;109:1260-5.
62. Cengel A, Turkoglu S, Turfan M, et al. Serum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failure. Acta cardiologica 2005;60:489-92. (Pubitemid 41433654)
63. Sakai H, Tsutamoto T, Tsutsui T, et al. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 2006;70:1006-11. (Pubitemid 44161737)
64. Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail 2011;17:25-30.
65. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004;555:589-606. (Pubitemid 38404582)
66. Boueiz A, Damarla M, Hassoun PM. Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol 2008;294:L830-40.
67. Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-64.
68. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003;107:1951-3. (Pubitemid 36506064)
69. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-24. (Pubitemid 34596038)
70. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-6. (Pubitemid 34761303)
71. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-16. (Pubitemid 44901524)
72. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11. (Pubitemid 33108372)
73. Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circulation research 2006;98:271-9.
74. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51:2301-9. (Pubitemid 351783365)
75. Harzand A, Tamariz L, Hare JM. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail 2012;18:179-82.
76. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. Jama 2000;283:2404-10. (Pubitemid 30257539)
77. Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-50. (Pubitemid 29325733)
78. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13. (Pubitemid 29310011)
79. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997;78:147-53. (Pubitemid 27404949)
80. Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9, 458 incident cases and 155, 084 controls: prospective study and meta-analysis. PLoS Med 2005;2:e76.
81. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170-80.
82. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995;141:637-44.
83. Goldberg RJ, Burchfiel CM, Benfante R, et al. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-year findings from the Honolulu Heart Program. Arch Intern Med 1995;155:686-94.
84. Liese AD, Hense HW, Lowel H, et al. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999;10:391-7. (Pubitemid 29288237)
85. Chien KL, Hsu HC, Sung FC, et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 2005;183:147-55.
86. Baba T, Amasaki Y, Soda M, et al. Fatty liver and uric acid levels predict incident coronary heart disease but not stroke among atomic bomb survivors in Nagasaki. Hypertens Res 2007;30:823-9. (Pubitemid 47578244)
87. Meisinger C, Koenig W, Baumert J, et al. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol 2008;28:1186-92.
88. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010;375:2161-7.
89. Johnson RJ, Tuttle KR. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. Hypertension 2000;35:E10.
90. Hicks M, Wong LS, Day RO. Identification of products from oxidation of uric acid induced by hydroxyl radicals. Free Radic Res Commun 1993;18:337-51.
91. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008;27:608-19. (Pubitemid 351948591)
92. Kuzkaya N, Weissmann N, Harrison DG, et al. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005;70:343-54. (Pubitemid 40905106)
93. Gersch C, Palii SP, Imaram W, et al. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 2009;28:118-49.
94. Robinson KM, Morre JT, Beckman JS. Triuret: a novel product of peroxynitrite-mediated oxidation of urate. Arch Biochem Biophys 2004;423:213-7. (Pubitemid 38198230)
95. Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008;27:967-78.
96. Kim KM, Henderson GN, Frye RF, et al. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:65-70.
97. Imaram W, Gersch C, Kim KM, et al. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med 2010;49:275-81.
98. Yu MA, Sanchez-Lozada LG, Johnson RJ, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010;28:1234-42.
99. Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008;26:269-75.
100. Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/ nitrosative stress. Am J Physiol Cell Physiol 2007;293:C584-96. (Pubitemid 47235197)
101. Cirillo P, Gersch MS, Mu W, et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 2009;20:545-53.
102. Chao HH, Liu JC, Lin JW, et al. Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin 2008;29:1301-12.
103. Sanchez-Lozada LG, Lanaspa-Garcia MA, Cristobal M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 2012;121:3-4.
104. Faires JS, McCarty DJ. Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals. Lancet 1962;280:682-5.
105. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-93. (Pubitemid 36706079)
106. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97. (Pubitemid 35386908)
107. Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol 2007;292:F116-22. (Pubitemid 46105250)
108. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174-81.
109. Schwartz IF, Grupper A, Chernichovski T, et al. Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. J Vasc Res 2011;48:252-60.
110. Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008;295:C1183-90. (Pubitemid 352790338)
111. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-42. (Pubitemid 40577708)
112. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol 2006;290:F625-31. (Pubitemid 43724964)
113. Kurra V, Eraranta A, Jolma P, et al. Hyperuricemia, Oxidative Stress, and Carotid Artery Tone in Experimental Renal Insufficiency. Am J Hypertens 2009;22:964-70.
114. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746-51. (Pubitemid 30165320)
115. Guthikonda S, Sinkey C, Barenz T, et al. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003;107:416-21. (Pubitemid 36158043)
116. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004;94:932-5. (Pubitemid 39349561)
117. El Solh AA, Saliba R, Bosinski T, et al. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur Respir J 2006;27:997-1002. (Pubitemid 44911115)
118. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 2011;20:182-7.
119. Yiginer O, Ozcelik F, Inanc T, et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 2008;97:334-40.
120. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011;6:1887-94.
121. Melendez-Ramirez G, Perez-Mendez O, Lopez-Osorio C, et al. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. Endocr Res 2012;37:1-6.
122. Yelken B, Caliskan Y, Gorgulu N, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012;77:275-82.
123. Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011;22:1382-9.
124. Eraranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens 2008;26:1661-8.
125. Saito I, Saruta T, Kondo K, et al. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 1978;26:241-7. (Pubitemid 8361291)
126. Gruskin AB. The adolescent with essential hypertension. Am J Kidney Dis 1985;6:86-90. (Pubitemid 15017770)
127. Ramsay LE, Auty RM, Horth CE, et al. Plasma uric acid concentration related to the urinary excretion of aldosterone and of electrolytes in normal subjects. Clin Sci 1975;49:613-6. (Pubitemid 8069099)
128. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448-57. (Pubitemid 32666327)
129. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004;66:1465-70. (Pubitemid 39298378)
130. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21. (Pubitemid 37237047)
131. Shi Y, Galusha SA, Rock KL. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol 2006;176:3905-8. (Pubitemid 44264366)
132. Kaufmann SH. Heat shock proteins and the immune response. Immunol Today 1990;11:129-36. (Pubitemid 20095097)
133. Nishizawa J, Nakai A, Matsuda K, et al. Reactive oxygen species play an important role in the activation of heat shock factor 1 in ischemic-reperfused heart. Circulation 1999;99:934-41. (Pubitemid 29094309)
134. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737-42.
135. Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009;30:96-116.
136. Fini MA, Elias A, Johnson RJ, et al. Contribution of uric acid to cancer risk, recurrence and mortality. Clin Transl Med 2012; in press.
137. Waring WS, Convery A, Mishra V, et al. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) 2003;105:425-30. (Pubitemid 37249168)
138. Waring WS, McKnight JA, Webb DJ, et al. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006;55:3127-32. (Pubitemid 44923652)
139. Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523-30.
140. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;5:e197